Protecting migrating birds from avian influenza

PlantPharm is a closely held biotechnology firm with a small team of dedicated, long-term personnel — some with more than 35 years of experience. The company has developed plant-based technologies for over 40 years and incorporated in 2008 specifically to advance this work.

PlantPharm has served as an independent R&D partner for large companies and has produced plant-based pharmaceuticals, including an edible Hepatitis B vaccine that successfully completed an FDA human clinical trial with efficacy matching the standard injectable version. Most recently, PlantPharm received a $900,000 USDA APHIS collaborative grant to develop a zoonotic COVID vaccine for animals to help prevent spillover to humans.

We value your support. Sign on at no cost using our form, where you can leave a message of support or encouragement and authorize us to share your conviction with others. You can even email your logo to us.

Typical vaccine R&D takes three to five years. PlantPharm already has preliminary success, intellectual property, and facilities in place. This positions the team to deliver a tested vaccine in approximately 24 months if development proceeds as planned.

No — and it does not need to. Birds vaccinate themselves simply by eating at established feeding stations along their normal migration routes. Any migratory bird that feeds on grain will be directly vaccinated. That coverage also reduces infection pressure on birds that are not natural grain feeders.

Scientific metapopulation models show that meaningful disease control scales with coverage, and the benefits become larger and more non-linear as more birds are protected. The more birds we vaccinate, the greater the number of downstream birds shielded from HPAI.

Cranes receive special attention because they travel thousands of miles along well-known flyways and gather in predictable wetlands already monitored by the U.S. Fish and Wildlife Service. Protecting these long-lived, slow-to-reproduce birds — especially the endangered whooping crane — helps safeguard genetically important populations while reducing the virus reservoir that threatens farmed poultry.

The high upfront costs of R&D and efficacy testing, combined with a relatively low expected return on investment, make this work a low priority for large pharmaceutical companies. If it were a high priority, they would already be pursuing it.

This creates an opportunity for a smaller, more agile company. PlantPharm is currently the only firm with a ready edible-vaccine manufacturing platform prepared to take on the challenge.

Support will come from individual donors, conservation groups, and any available government grant opportunities. PlantPharm was recently invited by the National Science Foundation to submit a proposal, which has been submitted. However, the government process can take more than six months before funding decisions are announced.

We do not believe the safety of migrating birds — including iconic crane populations — or the economic protection of America’s poultry industry should wait another half-year. With your help, we are ready to move forward today.

No. This is a PlantPharm initiative. Government agencies and universities are actively collaborating with us to help achieve the project objectives, including design of transformation cassettes, plant transformation, lyophilization, and immunological testing in captive mallards.

As with any scientific R&D effort, success is not guaranteed. PlantPharm is staking its reputation and future on the successful development of a low-cost, edible HPAI vaccine that can be delivered at bait stations to protect both wild migrating flocks and the U.S. poultry sector.

The vaccine uses PlantPharm’s plant-edited expression system to produce HPAI hemagglutinin antigens together with a proprietary Toll-like receptor agonist / Heat Shock fusion protein immunostimulant already shown safe and effective in human studies. The final product is a lyophilized powder or pellet mixed into the pre-bait feed that USFWS biologists already place at monitored stations. No living plants or seed are released into the environment.

Safety and immune-response data will first be generated in captive mallards by the USGS; those results, plus subsequent controlled studies, form the foundation for any later field use. Key platform components have prior safety data; the specific migratory-bird formulation remains under active research and development.

As a wildlife and veterinary biologic intended for environmental delivery, development will follow the applicable USDA APHIS pathways for animal biologics. Coordination with the U.S. Fish and Wildlife Service will be required for any use connected to federal monitoring or banding stations.

PlantPharm’s earlier experience — an FDA-cleared human edible Hepatitis B vaccine trial and a recent USDA APHIS collaborative grant — provides relevant regulatory familiarity. Proof-of-concept and controlled studies are designed to generate the data packages needed for those reviews.

The immediate phase focuses on five parallel work-streams:

1. Design of transformation cassettes
2. Creation of edited plantlets
3. Plant multiplication and production
4. Optimization of lyophilization and packaging for bait-station stability
5. Immunological testing in captive mallards

Success at this stage is measured by antigen expression levels, product stability, detectable mucosal and systemic immune responses, and practical acceptance of the vaccine-containing feed. Later controlled or semi-field studies will assess uptake under more natural congregation conditions. Metapopulation modeling will help translate coverage data into expected reductions in transmission — especially for the long-distance populations that concentrate at monitored wetlands.

Yes. HPAI is a panzootic that has already moved into dairy cattle, other mammals that scavenge infected birds, and occasionally people through zoonotic contact. By lowering viral circulation and shedding among the primary wild-bird reservoirs and long-distance vectors — especially at the dense congregation sites where transmission is highest — an effective oral vaccine is expected to reduce opportunities for interspecies spillover.

This public-health co-benefit is secondary to the core wildlife and poultry goals but is an important additional reason the work matters for both migrating flocks and rural economies.

The plant-expression platform is intentionally modular: updated hemagglutinin sequences from circulating clades can be inserted into the same optimized expression system. Because production is plant-based rather than egg- or cell-culture-based, new versions can be generated and scaled more rapidly and at lower cost.

The proprietary immunostimulant is included specifically to strengthen both innate and adaptive mucosal responses. Duration of immunity will be characterized in the USGS mallard studies and follow-on work; those data will guide recommended re-baiting intervals if needed — critical for protecting multi-year crane cohorts that return to the same stopover sites.

The International Crane Foundation is listed among the project’s technical-support partners. They were the very first to endorse this edible vaccine initiative and have provided both inspiration and guidance. Cranes receive special emphasis because they are long-lived, slow to reproduce, travel predictable flyways, and congregate in wetlands already monitored and baited by USFWS.

Protecting these populations — especially the endangered whooping crane — helps safeguard genetically important groups while simultaneously reducing a key viral reservoir that threatens commercial poultry. Healthy crane flocks also support wetland ecosystems and the communities and birders who value them across North America.

Because the core plant-based manufacturing platform already exists, the cost of moving into full proof-of-concept is substantially lower than starting a traditional vaccine program from scratch. Early funding accelerates the five work-streams (cassette design, plant transformation, plant multiplication and production, lyophilization and packaging, and captive-bird immunology), covers coordination with USFWS and the International Crane Foundation, and supports the regulatory data packages.

Detailed milestones are shared under confidentiality with serious supporters. We are deliberately not waiting for slower government-grant cycles when an extra migration season of unprotected birds — and continued poultry risk — can be avoided.

The final vaccine product is a processed, lyophilized powder or pellet — not living plants, pollen, or seed. It is mixed in small quantities into the same pre-bait feed already used at existing, monitored stations.

Environmental risk assessment is an integral part of the planned studies and regulatory pathway. The strategy deliberately limits distribution to the fewest effective, already-established sites rather than broad landscape application — protecting both the birds and the wetlands they depend on.